Negative result: Atomo Diagnostics (ASX: AT1) shares plunge 18% on half-year earnings

What did the diagnostics report in its results?

| More on:
a woman winces as she inserts a home diagnostic test for COVID-19 up her nose with her sofa in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Atomo Diagnostics share price is sinking more than 18% on Tuesday
  • The company's half-yearly results show gross profit fell 30% to $1.76 million 
  • Atomo believes the diagnostic market has permanently changed. 

The Atomo Diagnostics Ltd (ASX: AT1) share price is falling today after the company reported its half-year results.

The company's shares are currently swapping hands at 14.7 cents each, a loss of 18.33% on the day so far.

Let's take a look at what the diagnostic testing company reported to the market after close yesterday.

Atomo share price slips amid half-year results

Highlights of the company's half-year (H1 FY22) results include:

  • Gross profit fell 30% to $1.76 million, down from $2.52 million in the previous corresponding period (PCP)
  • Gross margin of 33%, down from 55% in the PCP
  • Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) of -$1.48 million
  • Revenue up 17% on PCP (H1FY21) to $5.34 million
  • Cash balance of $13.68 million at 31 December 2021

What else happened in the half?

The company said its overall gross revenue from customers grew 53% to $7 million versus the PCP. This was driven by the huge demand for COVID-19 tests. There was also growth in sales of HIV self-tests.

Atomo sold 420,000 rapid COVID tests in the first half of the 2022 financial year although the company said its January sales have outstripped total sales for the entire first half. Since then, however, market demand has fallen as "Omicron infection rates drop and free government tests impact the market".

Nonetheless, the company has more than 120 enterprise and government customers and is still seeing demand for its products.

Management commentary

In its investor presentation, Atomo said Therapeutic Goods Administration (TGA) has "significantly relaxed" conditions of supply related to home-use, self-test products in Australia.

Given greater acceptance of home testing in the community Atomo sees an opportunity to commercialise a range of rapid tests in the local market and has first mover advantage in HIV as well as established consumer product support established in country.

What's next

In the near term, Atomo sees "immediate" revenue growth potential for COVID rapid testing. In the medium term, it foresees consumers globally accepting rapid testing in the home and the increased importance of home-based healthcare solutions.

Long term, it predicts fewer regulatory barriers to home testing, particularly in the United States. It expects well-capitalised market entrants building home-delivered healthcare will emerge. And there will be more demand for convenient healthcare services.

The company said the diagnostic market has "permanently changed".

Atomo believes it can continue to meet demand for COVID tests in the Australian and New Zealand markets. HIV testing is also an opportunity and Atomo plans to target commercial agreements in the USA and China. The company also believes it has "first mover" advantage on Australia's HIV self-test market.

The company's cash balance has increased by more than $2 million since 31 December to $15.8 million at 31 January 2022.

Atomo Diagnostics share price summary

The Atomo Diagnostics share price has sunk 46% in the past year and is down 50% year to date.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned around 5% over the past year.

Atomo has a market capitalisation of roughly $61 million based on today's share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

Photo of two women shopping.
Earnings Results

Premier Investments share price jumps 9% on results and demerger plans

The Smiggle and Peter Alexander owner has released its results. How did it perform?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Earnings Results

Soul Patts share price struggles on falling profits

ASX 200 investment house Soul Patts reported its half year results this morning.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Earnings Results

Brickworks share price tumbles on disappointing half-year loss

This loss didn't stop the company from increasing its dividend again.

Read more »

A man sits on a bench atop a mountain with a laptop, making investments with a green ESG mind.
Earnings Results

ASX All Ords stock KMD tumbles as interim dividend cancelled

Investors are hitting the sell button on ASX All Ords stock KMD today.

Read more »

Coal miner holding a giant coal rock in his hand making a circle with his hand, symbolising a rising share price.
Energy Shares

New Hope share price charges higher despite profit crunch and huge dividend cut

Weaker coal prices have hit this miner's profits and dividend hard.

Read more »

A Chinese investor sits in front of his laptop looking pensive and concerned about pandemic lockdowns which may impact ASX 200 iron ore share prices
Earnings Results

Liontown share price tumbles 7% on half-year results

This lithium developer's results have been released this afternoon.

Read more »

A man in a hard hat and high visibility vest holds his thumb up in a gesture of confidence with heavy moving equipment in the background as on a mine site as the Chalice Mining share price rises today.
Earnings Results

Sayona Mining share price jumps despite $32m half-year loss

The Sayona Mining Ltd (ASX: SYA) share price is pushing higher on Thursday. At the time of writing, the lithium…

Read more »